Emerging Therapies for Dystrophic Cardiomyopathy

Daniel J. Garry; Tamas Alexy

doi:10.1016/j.jacbts.2019.10.003

Emerging Therapies for Dystrophic Cardiomyopathy

Daniel J. Garry, Tamas Alexy

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	792-794
Number of pages	3
Journal	JACC: Basic to Translational Science
Volume	4
Issue number	7
DOIs	https://doi.org/10.1016/j.jacbts.2019.10.003
State	Published - Nov 2019

Bibliographical note

Funding Information:
Dr. Garry has received grants from Regenerative Medicine Minnesota (RMM), the American Heart Association, the National Institutes of Health, and the Department of Defense. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Keywords

cardiomyopathy
diastolic dysfunction
dystrophin
recombinant adeno-associated virus vectors
ribonucleotide reductase

Access

10.1016/j.jacbts.2019.10.003

OpenUrl availability

Full text

Cite this

@article{25a1b6378b844a15912cdc2e6e4cbb8b,

title = "Emerging Therapies for Dystrophic Cardiomyopathy",

keywords = "cardiomyopathy, diastolic dysfunction, dystrophin, recombinant adeno-associated virus vectors, ribonucleotide reductase",

author = "Garry, {Daniel J.} and Tamas Alexy",

note = "Funding Information: Dr. Garry has received grants from Regenerative Medicine Minnesota (RMM), the American Heart Association, the National Institutes of Health, and the Department of Defense. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2019",

month = nov,

doi = "10.1016/j.jacbts.2019.10.003",

language = "English (US)",

volume = "4",

pages = "792--794",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Emerging Therapies for Dystrophic Cardiomyopathy

AU - Garry, Daniel J.

AU - Alexy, Tamas

N1 - Funding Information: Dr. Garry has received grants from Regenerative Medicine Minnesota (RMM), the American Heart Association, the National Institutes of Health, and the Department of Defense. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2019/11

Y1 - 2019/11

KW - cardiomyopathy

KW - diastolic dysfunction

KW - dystrophin

KW - recombinant adeno-associated virus vectors

KW - ribonucleotide reductase

UR - http://www.scopus.com/inward/record.url?scp=85074930225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074930225&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2019.10.003

DO - 10.1016/j.jacbts.2019.10.003

M3 - Article

C2 - 31999276

AN - SCOPUS:85074930225

SN - 2452-302X

VL - 4

SP - 792

EP - 794

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 7

ER -

Emerging Therapies for Dystrophic Cardiomyopathy

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Cite this